Advanced Search

Study Preview



Study Title and Description

Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection.



Key Questions Addressed
6 Key Question 6. What is the effectiveness of currently recommended antiviral treatments in improving health outcomes in patients with HCV infection?
  • Comments Comments (
    0
    ) |
7 Key Question 7. What is the effectiveness of currently recommended antiviral treatments in achieving a SVR in patients with HCV infection?
  • Comments Comments (
    0
    ) |
8 Key Question 8. What are the harms of currently recommended antiviral treatments?
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection.
Author Wirth S., Rosenthal P., Gonzalez-Peralta RP., Jonas MM., Balistreri WF., Lin CH., Hardikar W., Kersey K., Massetto B., Kanwar B., Brainard DM., Shao J., Svarovskaia E., Kirby B., Arnon R., Murray KF., Schwarz KB.
Country Helios Medical Center, Witten/Herdecke University, Wuppertal, Germany.
Year 2017
Numbers Pubmed ID: 28543053

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Key Questions 1-9


Results & Comparisons

No Results found.